United StatesÚltimas notícias

AstraZeneca (NASDAQ:AZN) unveiled positive data from its late-stage EMERALD-3 clinical trial on Monday, demonstrating that adding its dual-immunotherapy regimen to standard localized therapy significantly slows disease progression in patients battling early-stage, unresectable liver cancer.

Kamada (NASDAQ:KMDA) announced Monday that the U.S. Food and Drug Administration has approved its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) rabies virus neutralization laboratory at its manufacturing plant in Beit Kama, Israel.

Torsten Slok, chief economist at Apollo, explains what people are getting wrong about the impact of AI on the US labor market.

Marex Group (NASDAQ:MRX) announced Monday that it has acquired Levmet, a Monaco-based liquidity provider, in a move to strengthen its physical market-making operations and secure a firmer foothold in European power and gas trading.

Jade Biosciences (NASDAQ:JBIO) delivered a significant milestone for its autoimmune pipeline, reporting positive interim results from its Phase 1 clinical trial evaluating JADE101.

Monopar Therapeutics (NASDAQ:MNPR) announced encouraging mid-stage clinical results for its investigational Wilson disease therapy, demonstrating widespread stabilization in liver pathology alongside substantial neurological and quality-of-life improvements.

C1 Fund (NYSE:CFND) released its financial results for the first quarter ended March 31, 2026, revealing a net asset value (NAV) of $48,906,337, or $7.34 per share, against a backdrop of accelerating initial public offering activity within its private digital asset portfolio.

The artificial-intelligence trade locked in fresh gains on Monday, allowing global equities to shrug off a rebound in oil prices as the US and Iran remained deadlocked over a peace deal. Ozan Tarman, Global Macro Vice Chair at Deutsche Bank joined Stephen Carroll and Lizzy Burden to discuss the the moves in stocks as where Bond yields go from here.

Citius Oncology (NASDAQ:CTOR) showcased positive early-stage clinical trial results, demonstrating the potential of its targeted immune therapy LYMPHIR to enhance the efficacy of checkpoint inhibitors in treating recurrent or refractory gynecologic cancers.

Invivyd (NASDAQ:IVVD) completed enrollment for the pivotal Phase 3 clinical trial of its leading monoclonal antibody candidate, positioning the biotechnology firm to deliver late-stage results later this quarter.

Science Applications International Corp. (NASDAQ:SAIC) raised its full-year profitability and earnings forecasts after a steady opening quarter marked by expanding operating margins and an accumulation of new federal contract awards.

Bristol Myers Squibb (NYSE:BMY) secured a major regulatory milestone on Monday as the European Commission approved its blockbuster immunotherapy Opdivo in combination with chemotherapy for patients fighting advanced blood cancer.